Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases

Figures & data

Figure 1. The number of new-diagnosed MM patients in our hospital.

Figure 2. The number of MM patients according age being diagnosed.

Table 1. The mean value and range of laboratory outcomes.

Items (unit)	Mean value	Range
Hemoglobin (g/L)	83	30–177
Scr (µmol/L)	85	29–1740
Alb (g/L)	35.2	11.4–56.2
Ca (mmol/L)	2.22	1.29–5.82
β2-MG (mg/L)	4.6	0.7–38.4
CRP (mg/L)	3.7	0.1–254
Ratio of plasma cells (%)	30.5	3–99
LDH (U/L)	176	59–1440

Table 2. The type of 787 MM patients.

Type	Number/rate (%)	Subtype	Number/rate (%)
Light-chain	188 (23.1)	K	79 (9.2)
		L	114 (13.9)
IgG	366 (46.6)	K	212 (26.4)
		L	154 (20.2)
IgA	203 (26.4)	K	102 (13.3)
		L	101 (13.1)
IgD	13 (1.7)	K	0 (0)
		L	13 (1.7)
IgM	5 (0.6)	K	4 (0.5)
		L	1 (0.1)
No-secreting	10 (1.3)	–	–
Double-clone	2 (0.2)	–	–

Table 3. The stage of 787 MM patients according to D–S and ISS.

Stage (D–S)	Number (%)	Stage (ISS)	Number (%)
Ia	98 (12.5)	I	263 (33.4)
Ib	5 (0.6)
IIa	84 (10.7)	II	273 (34.7)
IIb	16 (2.0)
IIIa	411 (52.2)	III	251 (31.9)
IIIb	173 (22.0)

Table 4. The relationship between clinical characteristics and overall survival.

Influence	n	Median survival time (months)	95% confidence interval	P value
Sex
Male	343	53	42.40–63.60	0.167
Female	205	61	48.17–73.83
Age
<60 years	245	63	53.81–72.19	0.005*
≥60 years	303	46	38.30–53.70
Hemoglobin (Hb)
<100 g/L	355	48	41.82–54.18	0.004*
≥100 g/L	193	65	59.38–70.62
Creatinine (Cr)
<176.8 mmol/L	425	60	51.16–68.83	0.001*
≥176.8 mmol/L	123	44	32.98–55.02
Albumin
<35 g/L	245	42	55.61–74.39	0.014*
≥35 g/L	303	65	35.92–48.08
Calcium
<2.75 mmol/L	498	60	52.57–67.43	0.001*
≥2.75 mmol/L	50	34	13.76–54.24
β2-microglobin
<5.5 mg/L	334	61	52.64–69.36	0.005*
≥5.5 mg/L	214	46	37.77–54.23
LDH
<240 U/L	429	60	51.70–68.31	0.001*
≥240 U/L	119	34	21.77–46.23
CRP
<8.2 mg/L	382	61	51.82–70.18	0.002*
≥8.2 mg/L	166	42	31.90–52.09
Bone lesion
0	203	65	46.33–83.67	0.586
1	152	68	46.06–89.94
2	193	53	43.49–62.50
Plasma cells
<30%	279	65	56.52–73.48	0.005*
≥30%	269	44	36.88–51.12
Abnormal plasma cells
≤0.8	251	65	51.00–79.00	0.016*
>0.8	297	46	45.00–61.00
D–S stage
I	73	80	52.57–107.44	0.001*
II	95	73	53.52–92.48
III	380	46	39.53–52.47
ISS stage
I	127	65	56.81–73.18	0.004*
II	207	53	38.36–67.64
III	214	46	37.77–54.23

*P < 0.05.